By leveraging our understanding of catalytic processes, scientists can design inhibitors that specifically target resistance-conferring enzymes. For instance, β-lactamase inhibitors are often combined with β-lactam antibiotics to block the enzyme's activity, thereby restoring the drug's effectiveness. Additionally, designing drugs that are poor substrates for resistance enzymes can also help mitigate the issue.
